YOLFTbeta
Aytu BioScience Inc

Aytu BioScience Inc

AYTU · NASDAQ · Healthcare / Drug Manufacturers - Specialty & Generic

1.78USD-0.01 (-0.56%)

Price History

Full chart

Market Stats

Previous Close1.79
Open1.77
Day Range1.75 – 1.85
52-Week Range1.65 – 3.07
Volume18.60K
Market Cap25.10M
P/E (TTM)0.00
Forward P/E9.16
EPS-1.16
Dividend Yield0.00%
Beta0.27
50-Day Avg2.22
200-Day Avg2.38

About

Aytu BioPharma, Inc., a pharmaceutical company, focuses on commercializing novel therapeutics in the United States and internationally. The company offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT extended-release orally disintegrating tablets for patients from six years of age and above; Cotempla XR-ODT extended-release orally disintegrating tablets for patients from six to seventeen years old; and Metadate CD, a central nervous system stimulant indicated for the treatment of ADHD. It also provides pediatric prescription product portfolio comprising Karbinal ER, an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions for patients two years and above; and Poly-Vi-Flor and Tri-Vi-Flor complementary prescription fluoride-based multi-vitamin products containing combinations of fluoride and vitamins in liquid and chewable tablet form for infants and children with fluoride deficiency. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu BioPharma, Inc. in March 2021. Aytu BioPharma, Inc. is headquartered in Denver, Colorado.

Company Details

  • SectorHealthcare
  • IndustryDrug Manufacturers - Specialty & Generic
  • CEOMr. Joshua R. Disbrow
  • Employees82
  • Headquarters7900 East Union Avenue, Denver, CO, United States, 80237, USA
  • Websitehttps://aytubio.com

Leadership

  • Mr. Joshua R. DisbrowCEO & Director · b. 1975
  • Mr. Ryan J. Selhorn CPACFO, Corporate Secretary & Treasurer · b. 1982
  • Mr. Jarrett T. Disbrow Ph.D.Chief Business Officer · b. 1975
  • Mr. Greg PyszczymukaChief Commercial Officer · b. 1979
  • Ms. Margaret CabanoVice President of Operations
  • Dr. Gerwin Westfield Ph.D.Senior Vice President of Scientific Affairs

Financials

Income Statement

Currency: USD2007-06-302008-06-302009-06-302010-06-302011-06-302012-06-302013-06-302014-06-302015-06-302016-06-302017-06-302018-06-302019-06-302020-06-302021-06-302022-06-302023-06-302024-06-302025-06-302026-06-30
Total Revenue--1.75K--1.75K1.75K58.93K261.78K2.56M3.22M3.66M7.32M27.63M65.63M96.67M107.40M65.18M66.38M57.57M
Growth (%)------0.00%+3267.37%+344.23%+878.85%+25.72%+13.61%+100.01%+277.47%+137.52%+47.29%+11.10%-39.31%+1.84%-13.27%
Cost of Revenue-------48.25K6.31M88.11K957.08K1.42M2.05M2.20M8.28M36.43M46.39M40.77M16.13M20.55M20.75M
Gross Profit--1.75K--1.75K50.00K58.93K173.67K1.61M1.80M1.61M5.12M19.35M29.20M50.28M66.63M49.05M45.83M36.82M
Gross Margin--100.00%--100.00%2857.14%100.00%66.34%62.65%56.00%43.97%69.92%70.03%44.49%52.02%62.04%75.26%69.04%63.95%
Operating Expense--57.57K--58.11K102.41K6.41M7.81M23.31M21.93M21.31M21.96M40.48M88.07M160.19M83.70M50.65M53.66M45.13M
Operating Income-46.89K-54.98K-55.82K-56.74K-133.62K-56.36K-52.41K-6.35M-7.63M-21.70M-20.13M-19.70M-16.85M-21.13M-58.87M-109.91M-17.07M-1.59M-7.83M-8.31M
Operating Margin---3189.83%---3220.34%-2995.09%-10770.31%-2915.53%-847.02%-624.70%-538.26%-230.13%-76.47%-89.70%-113.69%-15.89%-2.44%-11.79%-14.44%
EBITDA-40.47K-47.47K-47.54K-47.28K-126.86K-50.21K-47.47K-52.71K-7.51M-21.81M-18.13M-15.25M-14.61M-12.21M-29.04M-27.96M-3.27M1.41M-4.67M-4.38M
EBITDA Margin---2716.51%---2868.91%-2712.69%-89.44%-2870.37%-851.29%-562.80%-416.75%-199.59%-44.18%-44.25%-28.92%-3.05%2.16%-7.03%-7.62%
Net Income-48.95K-57.17K-58.89K-60.27K-136.80K-59.67K-57.32K-5.58M-7.72M-28.18M-22.51M-10.19M-47.17M-13.62M-58.29M-108.78M-17.05M-15.84M-13.56M-14.25M
Net Income Margin---3365.37%---3410.00%-3275.31%-9466.80%-2950.32%-1099.73%-698.67%-278.36%-644.33%-49.29%-88.81%-112.53%-15.88%-24.31%-20.43%-24.76%
R&D------2.76M4.06M3.42M6.32M1.35M167.59K589.07K1.72M5.62M12.66M4.09M2.77M1.33M0
R&D as % of Total Revenue------157484.00%6888.30%1307.71%246.63%41.84%4.58%8.05%6.23%8.57%13.10%3.81%4.25%2.00%0.00%
Interest Expense2.06K03.07K3.80K3.18K3.32K4.90K4.23K114.99K5.49M2.53M749.42K0037.53M147.50M4.96M4.79M3.70M1.90M
Interest Expense % of Total Revenue--175.54%--189.66%280.23%7.18%43.93%214.31%78.67%20.48%0.00%0.00%57.18%152.58%4.62%7.35%5.58%3.29%

Balance Sheet

Currency: USD2007-06-302008-06-302009-06-302010-06-302011-06-302012-06-302013-06-302014-06-302015-06-302016-06-302017-06-302018-06-302019-06-302020-06-302021-06-302022-06-302023-06-302024-06-302025-06-302026-06-30
Total Assets59.67K74.07K41.85K27.09K22.84K12.65K9.67K12.02M18.23M24.34M15.00M21.06M34.72M152.84M265.67M137.62M137.84M118.86M124.18M105.01M
Total Liabilities40.87K48.12K55.44K82.70K58.43K82.36K120.53K6.65M2.61M14.26M11.00M7.64M27.63M57.82M128.10M93.31M98.48M91.14M105.21M69.73M
Total Equity18.81K25.96K-13.58K-55.61K-35.59K-69.72K-110.86K5.37M15.62M10.09M4.00M13.42M7.09M95.02M137.57M44.31M39.36M27.72M18.97M35.27M
Cash23.36K37.64K13.61K1.54K3.99K1091.86K2.64M7.35M8.05M802.33K7.01M11.04M48.08M49.65M19.36M22.98M20.01M30.95M26.31M
Total Debt34.40K48.12K54.62K77.60K52.30K68.05K99.51K4.60M-----12.45M30.97M18.19M30.43M16.42M22.94M18.11M
Net Debt11.04K10.47K41.00K76.05K48.31K67.94K97.65K1.96M-7.35M-8.05M-802.33K-7.01M-11.04M-46.07M-18.68M-1.17M7.44M-3.59M-8.02M-8.20M

Cash Flow

Currency: USD2007-06-302008-06-302009-06-302010-06-302011-06-302012-06-302013-06-302014-06-302015-06-302016-06-302017-06-302018-06-302019-06-302020-06-302021-06-302022-06-302023-06-302024-06-302025-06-302026-06-30
Operating Cash Flow-27.92K-44.80K-46.63K-43.38K-64.82K-37.85K-37.70K-5.50M-6.63M-10.66M-13.83M-15.94M-13.83M-28.37M-25.96M-28.82M-5.13M-1.39M-1.94M3.28M
Investing Cash Flow--7.47K-7.47K-6.58K---338.92K-9.30K-1.00M-5.30M-3.53M-484.29K-1.06M-5.66M-2.78M-3.25M-117.00K-329.00K-2.56M-29.00K
Financing Cash Flow2.40K66.55K22.60K37.88K67.27K33.97K39.46K5.24M12.35M16.66M10.19M22.66M19.08M71.07M30.31M1.53M8.87M-1.26M15.44M-7.90M
Capital Expenditure07.47K06.58K008.92K9.30K252.93K2.25M111.61K74.71K59.85K5.85M2.34M2.34M0329.00K3.23M29.00K
Free Cash Flow-27.92K-52.27K-46.63K-49.95K-64.82K-37.85K-46.62K-5.51M-6.63M-12.91M-13.94M-16.02M-13.89M-28.37M-25.96M-28.82M-5.13M-1.72M-5.17M3.25M
Dividends Paid--------27.48K-----------
FCF to OCF100.00%116.67%100.00%115.16%100.00%100.00%123.66%100.17%100.00%121.14%100.81%100.47%100.43%100.00%100.00%100.00%100.00%123.70%266.65%99.12%
Dividend Paid to FCF---------0.41%-----------

Earnings

Report DateNov 30, 2008Feb 28, 2009May 31, 2009Aug 31, 2009Nov 30, 2009Feb 28, 2010May 31, 2010Aug 31, 2010Nov 30, 2010Feb 28, 2011May 31, 2011Aug 31, 2011Nov 30, 2011Feb 29, 2012May 31, 2012Aug 31, 2012Nov 30, 2012Feb 28, 2013May 31, 2013Aug 31, 2013Nov 30, 2013Feb 28, 2014May 31, 2014Aug 31, 2014Nov 30, 2014Feb 28, 2015Mar 31, 2015Sep 30, 2015Dec 31, 2015May 11, 2016Sep 1, 2016Nov 7, 2016Feb 9, 2017May 11, 2017Aug 31, 2017Nov 9, 2017Feb 8, 2018May 14, 2018Sep 6, 2018Nov 7, 2018Feb 7, 2019May 14, 2019Sep 26, 2019Nov 14, 2019Feb 14, 2020May 15, 2020Sep 24, 2020Nov 12, 2020Feb 11, 2021May 17, 2021Sep 27, 2021Nov 15, 2021Feb 14, 2022May 16, 2022Sep 27, 2022Nov 14, 2022Feb 21, 2023May 11, 2023Sep 27, 2023Nov 14, 2023Feb 14, 2024May 15, 2024Sep 25, 2024Nov 13, 2024Feb 12, 2025May 14, 2025Sep 23, 2025Nov 13, 2025Feb 3, 2026May 13, 2026Sep 22, 2026Nov 12, 2026
EPS Estimate-------------------------------3120.00-51466.67-34666.67-34000.00-34400.00-8080.00-7120.00-4000.00-18.60-290.00-79.00-116.00-66.00-55.00-68.00-10.00-0.35-11.00-8.80-6.30-9.80-1.60-11.60-8.20-7.40-3.600.20-0.80-0.95-0.04-0.25-0.64-0.45-0.34-0.28-0.170.53-0.19-0.49-0.42-0.22-0.01
EPS Actual-76660.46-54772.57-32675.24-38522.20-64223.40-41169.94-49907.89-47121.66-59324.87-76516.21-57430.00-204941.84-48261.30-24595.51-28846.94-43291.50-47718.48-32648.91-31707.14-25209.36-39236.99-52752.16-27003.45-22814.06-31997.56-19777.29-482161.34-153239.13-224344.53-1854.38-9092.00-93600.00-48800.00-38400.00-16640.00-7040.00-3560.00-960.000.29-392.00-144.00-100.00-84.12-64.00-2.00-30.00-0.20-8.00-9.00-21.82-15.00-6.44-8.80-35.80-9.80-1.20-1.32-1.93-0.59-1.48-0.04-0.52-0.82-0.150.130.21-2.93-0.09-0.23-0.41-0.05-
Surprise-------------------------------191.41%-81.87%-40.77%-12.94%51.63%12.87%50.00%76.00%101.56%-35.17%-82.28%13.79%-27.45%-16.36%97.06%-200.00%42.86%27.27%-2.27%-246.35%-53.06%-302.50%24.14%-336.59%-32.43%66.67%-760.00%-141.25%37.89%-3600.00%84.00%18.75%-82.22%55.88%146.43%223.53%-652.83%52.63%53.06%2.38%77.27%-
Timing-----------------------------After-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketPre-marketAfter-hoursAfter-hoursAfter-hoursPre-market-After-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hours-After-hoursAfter-hoursAfter-hoursAfter-hours-

Key Statistics & Ratios

Market Cap25.10M
Enterprise Value15.61M
Trailing P/E0.00
Forward P/E9.16
PEG Ratio0.00
Price / Sales0.44
Price / Book0.71
EPS-1.16
Book Value3.27
Revenue (TTM)57.57M
Gross Profit (TTM)36.82M
EBITDA-4.38M
Profit Margin-24.76%
Operating Margin-4.82%
Return on Equity-52.55%
Return on Assets-4.54%
Shares Outstanding10.87M
Shares Float7.65M
Beta0.27
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Buy
Based on 1 analystsTarget 9.50
  • Buy
    1

Ownership Breakdown

Institutions
35.51%
Insiders
8.16%
Retail / Other
56.33%

Top Institutional Holders

  • Nantahala Capital Management, LLC
    1.09M10.13%
  • Stonepine Capital Management Llc
    792.29K7.38%
  • Awm Investment Company Inc
    619.57K5.77%
  • Vanguard Capital Management, LLC
    261.15K2.43%
  • CROWN ADVISORS MANAGEMENT, INC.
    200.00K1.86%
  • Diadema Partners LP
    148.55K1.38%
  • Two Sigma Investments LLC
    105.33K0.98%
  • Renaissance Technologies Corp
    93.72K0.87%
  • Persistent Asset Partners Limited
    92.90K0.87%
  • Geode Capital Management, LLC
    92.64K0.86%
  • Arete Wealth Advisors, LLC
    49.55K0.46%
  • Citadel Advisors Llc
    49.41K0.46%
  • Vanguard Fiduciary Trust Co
    47.05K0.44%
  • Dimensional Fund Advisors, Inc.
    45.33K0.42%
  • Bellevue Asset Management, LLC
    25.01K0.23%
  • BlackRock Inc
    22.79K0.21%
  • XTX Topco Ltd
    21.58K0.20%

Top Fund Holders

  • Vanguard MStar Total Stk Mkt Idx Invest
    169.00K1.57%
  • Fidelity Extended Market Index
    48.91K0.46%
  • Perritt MicroCap Opportunities Investor
    20.00K0.19%

Stock Splits

  • Jan 6, 20231:20
  • Dec 9, 20201:10
  • Aug 13, 20181:20
  • Aug 29, 20171:20
  • Jul 1, 20161:12
  • Jun 10, 201582:1000